BYSI
BeyondSpring Inc. NASDAQ Listed Mar 9, 2017$1.47
Mkt Cap $60.4M
52w Low $1.21
11.7% of range
52w High $3.44
50d MA $1.61
200d MA $1.76
P/E (TTM)
-7.5x
EV/EBITDA
-6.6x
P/B
—
Debt/Equity
-0.0x
ROE
3.1%
P/FCF
-3.3x
RSI (14)
—
ATR (14)
—
Beta
0.51
50d MA
$1.61
200d MA
$1.76
Avg Volume
19.9K
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.
28 Liberty Street · Florham Park, NY 10005 · US
Data updated apr 24, 2026 11:30pm
· Source: massive.com